viernes, 2 de octubre de 2026

Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial Prof Sheraz Yaqub, MD PhDa,b Send email to sheraz.yaqub@medisin.uio.no ∙ Morten Valberg, PhDc ∙ Bjørn Atle Bjørnbeth, MD PhDa ∙ Jon-Helge Angelsen, MD PhDd,e ∙ Kristoffer Watten Brudvik, MD PhDa ∙ Ina Andrassy Eilertsen, PhDf ∙ et al.

Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial Prof Sheraz Yaqub, MD PhDa,b Send email to sheraz.yaqub@medisin.uio.no ∙ Morten Valberg, PhDc ∙ Bjørn Atle Bjørnbeth, MD PhDa ∙ Jon-Helge Angelsen, MD PhDd,e ∙ Kristoffer Watten Brudvik, MD PhDa ∙ Ina Andrassy Eilertsen, PhDf ∙ et al. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00260-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ihpba26&_hsenc=p2ANqtz-8dpguG_cBBSA_NrbdyonXHBGmFr4osFo9lOq9RKriYu6U80R_1teTApjRFgVKd2oNEAiPxK_XfhJjrHNxXwhbvvJ3HDw&_hsmi=442102189&utm_source=hs_email

No hay comentarios:

Publicar un comentario